Abstract Innate immunity may activate paracrine circuits able to entail vascular system in the onset and progression of several chronic degenerative diseases. In particular, interleukin (IL)-12 triggers a genetic program in lymphomononuclear cells characterized by the production of interferon-c and specific chemokines resulting in an angiostatic activity. The aim of this study is to identify molecules involved in the regulation of cell cycle in endothelial cells co-cultured with IL-12-stimulated lymphomonuclear cells. By using a transwell mediated coculture system we demonstrated that IL-12-stimulated lymphomonuclear cells induce an arrest of endothelial cells cycle in G1, which is mainly mediated by the up-regulation of p21
Introduction
Tumor aggressiveness is preceded by a prominent vascularization, caused by an alteration of homeostasis between endogenous inhibitors and inducers of angiogenesis [1] . This unbalance is mainly caused by mutations of molecules involved in the control of transcription of angiogenesis related genes [1] and by networks occurring between cancer and inflammatory cells [2] . Activation of these circuits results in the formation of a chaotic and inefficient circulation, which represents the final target of antiangiogenic therapies aimed to normalize, rather than to inhibit, the architecture and the function of tumor vasculature [3] . A similar scenario occurs in chronic inflammatory diseases [4] , including atherosclerosis [5] . The clinical significance of plaque neovascularization is indicated by studies that show a higher prevalence of angiogenesis in atherosclerotic lesions characterized by plaque instability [6, 7] . Endogenous angiogenesis inhibitors are produced during normal or pathological situations and may be Marina Strasly and Claudia Meda contributed equally to this work.
Electronic supplementary material
The online version of this article (doi:10.1007/s10456-012-9286-9) contains supplementary material, which is available to authorized users. cryptic domains of matrix proteins cleaved by matrix metalloproteinases, or soluble molecules taking part in tissue homeostasis, including cytokines and chemokines [1] . Within cytokines, interleukin (IL)-12 is a powerful inhibitor of tumor progression [reviewed in [8] ]. It is mainly involved in connecting innate and adaptive immunity through the production of interferon (IFN)c [9] .
Numerous preclinical and clinical studies have demonstrated that the inhibition of tumor growth is mediated by multiple activities of IL-12 including Th1 responses, CD8
? cell-, NK cell-and granulocyte-mediated cytotoxicity, and vascular targeting. Besides promoting tumor ischemichemorrhagic necrosis by recruiting leucocytes, IL-12 inhibits angiogenesis [10] [11] [12] [13] [14] , without a direct stimulation of endothelial cells (ECs) [15] . This effect appears to be dependent on the ability of T and NK cells stimulated by IL-12 to release IFNc, which modulates the induction of angiostatic chemokines CXCL9, CXCL10 and CXCL11 [14, 16, 17] . These chemokines exert their activity by activating CXCR3B receptor expressed on ECs [18] and inhibiting the motility and the proliferation triggered by angiogenic inducers [16, 17, [19] [20] [21] .
Furthermore the IL-12/IFNc/chemokine axis participates in regulatory networks occurring between lymphocytes and ECs. By using a co-culture model avoiding cell contact we previously demonstrated that this axis delays the entry of ECs into S phase of their duplicative cycle without affecting survival, and alters proteolytic homeostasis, resulting in the inhibition of in vitro formation of capillarylike structures [22, 23] .
Cell-cycle progression relies on the activation of cyclins and cyclin-dependent kinases (CDK), which sequentially act together in G1 to initiate S phase and in G2 to initiate mitosis. These events are negatively regulated by two families of inhibitors. Inhibitor of cyclin-dependent kinase (INK)4 proteins, including p15, p16, p18 and p19, characterize the first class, which is specific for CDK4-6 and therefore its regulatory role is restricted to the early G1 phase. The second family is composed of Cip/Kip proteins, including p21, p27 and p57, and is not specific for a particular phase of the cycle [24] . In this study we report that IL-12-stimulated peripheral blood mononuclear cells (PBMCs) inhibit angiogenesis in chick chorion allantoid membrane (CAM) angiogenesis assay and describe specific stimulation of CDK inhibitor p21
Cip1/Waf1 in ECs triggered by PBMCs stimulated with IL-12.
Materials and methods

Cells
Human ECs from cord umbilical veins and PBMCs were prepared and used as described previously [22, 23, 25] .
Purified NK cells from PBMCs were obtained by magnetic bead isolation using MACS NK Negative Isolation kit (Miltenyi Biotech), according to the manufacturer's instructions. Purity was assessed by Cyan ADP cytofluorimeter (Beckman-Coulter). NK cells were routinely purified to [93 % with an average of 0.5 % contaminating CD14
? accessory cells. To purify CD4 ? and CD8 ? [22] , PBMCs were depleted of adherent cells by two 1-h rounds of adherence to plastic on tissue culture dishes at 37°C. Non-adherent cells were then incubated overnight at 4°C on a disk rotator with a combination of Abs against lineage-specific markers (HLA class II, CD19, CD14, CD56, CD11b, glycophorin, and CD4 or CD8; BD Biosciences). Subsequently, cells were washed, counted and incubated with magnetic beads coated with anti-mouse IgG mAbs (Dynal; final dilution, 40 beads/cell). After incubation, CD4
? or CD8 ? T cells were separated by negative immunomagnetic selection. The purity of the cellular subset evaluated by cytofluorimeter analysis was [95 %.
Mouse spleen cells (SPCs) were isolated from C57BL/6 mice (Charles River) [23] . Mouse aortic ECs were isolated from 12 weeks old p53 -/-mice (C57BL/6J-Trp53 tm1Tyj ) and p21
Cip1/Waf1-/-mice (B6;129S2-Cdkn1a tm1Tyj /J) (The Jackson Laboratory). Briefly, aortas were longitudinally opened, and placed with the intimal side downward onto a collagen I matrix in M199 medium (Sigma-Aldrich) supplemented with 10 % fetal calf serum (FCS) and 100 lg/mL EC growth supplement (Calbiochem) for 6 days. After tissue removal, trypsinized cells were pelleted and maintained on fibronectin-coated plates in endothelial basal medium (Sigma-Aldrich) [26] . ECs were characterized by cytofluorimeter analysis and were more than 92 % positive for Flk-1 (R&D Systems) and mucosal vascular addressin cell adhesion molecule-1 (Abcam).
Cell stimulation
PBMCs, CD4
? cells, CD8 ? cells, NK cells, and SPCs (3 9 10 6 /ml) were activated for 24 h with Con A (SigmaAldrich) (1.5 mg/ml) in the absence (activated cells) or in the presence of human IL-12 (R&D) (10 ng/ml) (stimulated cells). RPMI 1640 medium (Sigma-Aldrich) with 10 % FCS was used. Co-culture experiments were performed in Transwell systems (0.4 lm, BD Biosciences) with subconfluent ECs (7 9 10 4 ) plated at the bottom of the wells and lymphocytes (1.5-3 9 10 6 /ml) seeded onto the inserts. Both cell types were in RPMI 1640 medium with 10 % FCS [22, 23] .
CAM angiogenesis assay
Fertilized chicken eggs were incubated at 37°C in a humidified incubator. PBMCs, activated or stimulated PBMCs were resuspended to a final density of 1.5 9 10 6 cells in 50 ll of RPMI 1640 medium, embedded in Matrigel basement membrane matrix (BD Biosciences) and added on the CAM at day 10 of incubation with or without basic fibroblast growth factor (bFGF) (R&D Systems) (100 ng). After 48 h of incubation, CAMs were fixed with 3.7 % paraformaldehyde for 10 min at room temperature. Pictures were taken with a JVC TK-C1380E color video camera (ImageProPlus 4.0 imaging software) connected to the stereomicroscope (model SZX9; Olympus). Pictures were processed with the imaging software winRHIZO Pro (Regent Instruments Inc.) [27] .
Immunoprecipitation, immunobloting and cell extract preparations Immunoprecipitation and blot analysis were performed accordingly to our routine procedures on ECs [25] . Lysis buffer contained protease and phosphatase inhibitors, and Triton X-100 as detergent. For immunoprecipitation experiments cell lysates were divided into two aliquots: one part was immunoprecipitated as indicated, while the other part was kept unprocessed and directly used as control of the total level of co-immunoprecipated proteins.
In some experiments, protein detection was performed on nuclear, cytosolic or membrane fractions of ECs. To separate the cytosol from nuclear fraction, cells were lysed in 300 ll of ice cold lysis buffer (20 mM Tris-HCl, pH 8.0 containing 20 mM NaCl, 0.5 % Nonidet P-40, 1 mM DTT and protease and phosphatase inhibitors). Cells were resuspended by pipetting and then incubated on ice for 5-10 min. After centrifugation at 10,0009g for 10 min at 4°C, supernatant containing cytosolic proteins was collected and pellet was resuspended in 60 ll of 20 mM HEPES buffer (pH 8.0, containing protease inhibitors, 25 % glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 5 mM DTT). After 30 min on ice, suspension was centrifuged at 10,0009g for 10 min at 4°C and supernatant containing nuclear proteins was diluted (1:3) in the same buffer. To separate the cytosol from membrane fraction, ECs were harvested and rapidly sonicated at 4°C in 100 ll of 10 mM HEPES buffer (pH 7.5, containing 10 mM 2-mercaptoethanol, 5 mM EDTA, 10 % glycerol, 0.24 M sucrose and protease inhibitors). The lysate was centrifuged at 10,0009g for 40 min at 4°C. The supernatant, corresponding to the cytoplasmic fraction, was collected and membrane pellets were solubilized in the same buffer containing 1 % Triton X-100.
Western blot quantification was performed measuring band intensity by scan-densitometry with Phoretix 1D software (Nonlinear USA, Durham, NC). Changes in protein amount were quantified after normalization procedure.
The following Abs were used: anti-p21
Cip1/Waf1 (#AF1047; goat), anti-p27 kip1 (#AF2256; goat), anti-p53 (#AF1355; goat), anti-phospho-STAT1-Y701 (#AF2894; rabbit), anti-phosphop38 MAPK-T180/Y182 (#AF869; rabbit), anti-CD31 (#BBA7; mouse) were from R&D Systems; anti-p16
INK4b (sc-71805; mouse), anti-p18
INK4c (sc-9965; mouse), anti-p57 kip2 (sc-56341; mouse), anti-cyclin E (sc-56311; mouse), anti-Cdk2 (sc-53220; mouse), anti-STAT1 (sc-73070; mouse), antiphospho-STAT1-S727 (sc-16570; goat), anti-PKCd (sc-8402; mouse), anti-GAPDH (sc-48166; goat) were from Santa Cruz Biotechnology; anti-pan-p38 MAPK (#9212; rabbit), anti-p38a MAPK (#9228; mouse) were from Cell Signaling; anti-nuclear matrix p84 (ab94812) was from Abcam.
Cell cycle analysis
ECs were suspended in 50 ll of phosphate-buffered saline (pH 7.4) (PBS), fixed in 1 ml of 70 % ice-cold ethanol for 30 min on ice, stained with 0.5 ml of propidium iodide 100 lg/ml (Sigma-Aldrich) containing 5 lg/ml pancreatic RNase (Stratagene) for 20 min at 37°C. After gating out cellular aggregates and debris, propidium iodide fluorescence was measured by flow cytofluorometry, and cell cycle analysis was performed with the Mod Sit LT program (Verity Software House) [22, 23] . DNA synthesis was measured by 5-bromo-2-deoxyuridine (BrdU) uptake and compared with DNA content as determined by propidium iodide uptake [28] . Briefly, adherent cells were incubated with 30 lM BrdU (Sigma-Aldrich; 1 h at 37°C). Detached cells were fixed as described above, washed, and suspended in PBS. Cells were denatured in 1 ml of 2 N HCl for 20 min at room temperature and then neutralized with 1 ml of 0.1 M Na 2 B 4 O 7 for 5 min at room temperature. The cells were centrifuged and incubated (10 min at 45°C) in 2 ml of PBS containing 5 % Tween 20 and 0.1 % BSA, then centrifuged and incubated with 10 lg of fluoresceinated mAb anti-BrdU (PharMingen) in 0.2 ml of PBS for 30 min at room temperature in the dark. After washes the cells were kept overnight at 4°C in the dark to favor partial DNA renaturation. Staining with propidium iodide and flow cytofluorometry were performed as described above. At least 10,000 events were analyzed.
Protein down-modulation by siRNA
The day before oligofection, ECs were seeded at a density of 1 9 10 5 cells/well in 6-well plates. Two hundred pmoles of non-targeting (as control) or targeting siRNAs were transfected twice (at 0 and 24 h) in the presence of Lipofectamine (Invitrogen) according to manufacturer's protocol. siRNA duplexes for PKCd (AAG ATG AAG GAG GCG CTC AG) were obtained from Qiagen. In the case of p21
Cip1/Waf1 , STAT1 and p38 MAPK siGENOME SMART pools (Dharmacon) were used. Non-targeting duplexes were purchased from Dharmacon. 24 h after the second oligofection, ECs were lysed or tested in functional assays. Supplementary Figure S1 shows the level of target protein down-regulation exerted by specific targeting siRNAs. In some experiments, ECs carrying the target siRNAs were transfected with the vectors containing the cDNA corresponding to the gene of interest [pMT5-Flag-p21
Cip1/Waf1
(Addgene plasmid 16240), pLTR-PKCd (Addgene plasmid 8419), pRC/CMV-STAT1a-Flag (Addgene plasmid 8691), pRC/CMV-STAT1a S727A (Addgene plasmid 8700), pMT3-p38 (Addgene plasmid 12658)] by Lipofectamine.
Statistical analysis
Data are expressed by mean of at least 3-4 experiments and SD is indicated. Differences are analyzed by ANOVA followed by Bonferroni's test (SPSS Statistics 16.0).
Results
IL-12-stimulated PBMCs inhibit angiogenesis
We previously reported that ECs challenged with ConAactivated PBMCs stimulated with IL-12 modify their angiogenic in vitro potential as consequence of a reduction of proliferative rate and a modification of the proteolytic activity [22, 23] . We extended these observations to CAM angiogenesis assay. Matrigel containing PBMCs alone or with bFGF (100 ng) was applied to 10-day-old embryo CAMs. As shown in Fig. 1 , PBMCs or Con A-activated PBMCs (activated PBMCs) do not inhibit the bFGF-promoted CAM vessel branching and remodeling. On the contrary, activated PBMCs challenged with IL-12 (stimulated PBMCs) dramatically impaired the angiogenic effect triggered by bFGF (Fig. 1 ).
Stimulated PBMCs inhibit EC cycle through a p21
Cip1/Waf1 -dependent mechanism EC proliferation rate in CAM assay is very fast up to day 6, then starts to decline and it is reduced to half at day 10. The addition of an angiogenic molecule induces a clear increase in proliferative activity, which is evident after 2 days [29] . Therefore, we aimed at expanding our previous results that showed the blocking activity of stimulated PBMCs on EC cycle [23] . We investigated the expression of CDK inhibitors in ECs co-cultured for 48 h with PBMCs, activated PBMCs or stimulated PBMCs. p21 Cip1/Waf1 , a member of Cip/Kip family, seems to be the principal endothelial target. PBMCs alone slightly reduced the expression of p21 Cip1/Waf1 , which returned to the basal level in the presence of activated PBMCs and markedly increased with stimulated PBMCs (Fig. 2a) . This effect is mimicked by purified CD4 ? cells, but not by CD8 ? or NK cells (Fig. 2b) Figure S2) . The G1/S transition is dependent on activation of the cyclin E/Cdk2 complex, which is negatively regulated through the binding with p21
Cip1/Waf1 [30] . Figure 2c shows that more cyclin E and Cdk2 are recruited by p21
Cip1/Waf1 supporting the concept that stimulated PBMCs influence EC cycle at G1/S transition. Interestingly, PBMCs alone reduce the amount of cyclin E and Cdk2 associated with p21
Cip1/Waf1 while the interaction with Cdk2, but not with cyclin E is already promoted by activated PBMCs (Fig. 2c) .
A further analysis of the role of p21 Cip1/Waf1 was performed by using cells depleted of this protein. In a first set of experiments we used mouse aortic ECs isolated from p21
Cip1/Waf1-/-mice. SPCs activated by ConA (activated SPCs) and subsequently challenged with murine IL-12 (stimulated SPCs) induced a cell accumulation in G0/G1 phase and a reduction in S phase (Fig. 3a) . In striking contrast, the cell cycle of ECs from p21
Cip1/Waf1-/-mice resulted to be similar in all co-culture conditions (Fig. 3a) .
To further support the results obtained with p21
Cip1/Waf1-/--ECs, we silenced the expression of p21
Cip1/Waf1 in human ECs by RNA interference. After down-modulation of p21
Cip1/Waf1 , stimulated PBMCs were unable to arrest EC cycle in G1 phase (Fig. 3b) . However, after transfection of p21
Cip1/Waf1 cDNA, silenced ECs normally responded to stimulated PBMCs (Fig. 3b) . Of note, in ECs co-cultured with PBMCs the greater cell percentage observed in G1 phase is likely caused by transfection-induced overexpression of p21
Cip1/Waf1 that mimics the effect of p21 Cip1/Waf1 upregulation exerted by stimulated PBMCs on ECs.
Stimulated PBMCs modulate p21
Cip1/Waf1 by different mechanisms involving STAT1, PKCd, p38 MAPK, but not p53
The cellular amount of p21 Cip1/Waf1 is regulated at transcriptional level by both p53-dependent and -independent mechanisms [24] . Furthermore, post-transcriptional mechanisms involving mRNA or protein stabilization have been described to influence the cellular behavior of p21 Cip1/Waf1 [24, [31] [32] [33] [34] [35] . We firstly investigated the role of p53 tumor suppression protein that is considered pivotal in p21
Cip1/Waf1 regulation in stressed cells [24] . This aspect was studied by both evaluating the p53 expression in ECs co-cultured with PBMCs and by using ECs isolated from p53 -/-mice. Western blot analysis showed that p53 level did not change in ECs co-cultured with PBMCs or activated PBMCs but it dropped when ECs were co-cultured with stimulated PBMCs (Fig. 4a) . Furthermore ECs from p53 -/-mice normally responded to stimulated SPCs with an evident accumulation in G1 phase (Fig. 4b) . Altogether these data exclude a major role of p53 in up-regulating p21 Cip1/Waf1 . We previously demonstrated that IFNc is partially involved in EC response to stimulated PBMCs [23] . Indeed we investigated the role played by STAT1, a transcription factor that binds p21
Cip1/Waf1 promoter [36] and is involved in IFNc-mediated cell activation [37] . Stimulated PBMCs specifically induced an increase in STAT1 expression and phosphorylation on both Y701 and S727 (Fig. 5a) , as well as STAT1 nuclear translocation in co-cultured ECs (Fig. 5b) . The induced tyrosine phosphorylation and nuclear translocation of STAT1 indicates its activation [38] . Interestingly serine phosphorylation has been demonstrated to further enhance transcriptional activity at maximal levels [39] . Depletion of STAT1 by siRNA oligonucleotide (siSTAT1) transfection reduced the up-regulation of p21 Cip1/Waf1 induced by stimulated PBMCs (Fig. 5c ). This effect was partially and completely reversed by transfecting STAT1 depleted cells with S727A-STAT1 and STAT1 cDNAs, respectively (Fig. 5c) . In parallel, stimulated PBMCs-induced effect on G1/S transition was reduced in STAT1 depleted cells and rescued by transfecting STAT1 cDNA (Fig. 5d) .
A further mechanism of cell cycle control involves PKC pathway [40] . In particular PKCd is implicated in the regulation of G1/S progression through up-regulation of p21
Cip1/Waf1 [31, 35, 41, 42] . Blot analysis of cytosolic and membrane proteins isolated from ECs clearly indicated that PKCd was activated in cells co-cultured with stimulated PBMCs, as inferred by its translocation from cytosol to membrane fraction (Fig. 6a) . By depleting PKCd using the specific siRNA oligonucleotides (siPKCd), we investigated the role of this kinase in controlling p21
Cip1/Waf1 levels. The PKCd down-modulation by siPKCd markedly reduced the level of p21
Cip1/Waf1 in ECs co-cultured with stimulated PBMCs (Fig. 6b) . The role of PKCd was further supported by the use of the specific rottlein inhibitor [43] . As shown by Fig. 6c , 300 nM rottlein completely reverted the block of cell cycle in G1 phase observed in ECs cocultured with stimulated PBMCs.
Besides transcriptional mechanisms, p21 Cip1/Waf1 levels may be controlled by activation of p38 MAPK, which increases its stability [44, 45] . Stimulated PBMCs were able to raise the level of phosphorylated p38 in ECs (Fig. 7a) , and its depletion by a specific siRNA (sip38) reduced p21 Cip1/Waf1 increase ( Fig. 7b) and partially impaired the modulation of EC cycle by stimulated PBMCs (Fig. 7c) experiment performed with p38 cDNA indicated the specificity of the sip38 used (Fig. 7b, c) .
Discussion
Innate immunity is an emerging mechanism to control the vascular response to chronic injury. The circuit triggered by IL-12 released by activated dendritic cells or macrophages involves the production of IFNc and IFNc-inducible chemokines with angiostatic properties [16, 17, [19] [20] [21] . Firstly described in tumor [8] , the activation of this axis was subsequently reported in other diseases involving vascular system, such as atherosclerosis [6] . By using a coculture model, in previous reports we analyzed the cellular mechanisms required to accomplish the angiostatic activity of IL-12 [22, 23] . Our initial studies indicated that CD4 ? cells are the most important target of IL-12 to block ECs in G1 phase and that CD8
? and NK cells have cooperative functions. In this system, the IFNc axis and in particular CXCL9 and CXCL10 are the final effectors [23] . To better understand the signaling mechanisms involved, we focused on how PBMCs stimulated by IL-12 affect cycle progression in ECs. We showed that the CDK inhibitor p21
Cip1/Waf1 is a key molecule in the negative control of cycle progression. Actually, PBMCs or CD4 ? cells stimulated by IL-12 upregulate p21
Cip1/Waf1 expression in ECs and its function is crucial for EC cycle G1 arrest, as inferred by the use of ECs isolated from p21
Cip1/Waf1-/-mice and by the specific siRNA-mediated depletion. Other CDK inhibitors belonging to Cip/Kip or INK4 families are refractory to stimulated PBMCs suggesting that their role is marginal or absent. This result is consistent with the observation that p21
Cip1/Waf1 is the most important target of molecules inhibiting EC growth [26, [46] [47] [48] [49] [50] [51] [52] .
The mechanism by which stimulated PBMCs increase the level of p21
Cip1/Waf1 needs the combined activities of several regulatory pathways that confer some degrees of specificity to this system. By the use of different strategies we demonstrated the active function of STAT1, PKCd and p38 MAPK and excluded a role of p53 in regulating p21
Cip1/Waf1 levels and in control of EC cycle. In contrast to other biological contexts, such as the activity of antiangiogenic compounds, the effect of shear stress and senescence [46, 47, 51, 53, 54] , p21
Cip1/Waf1 activation in ECs challenged with stimulated PBMCs does not require p53 pathway. The demonstration was obtained by using ECs isolated from p53 -/-mice. These cells normally Figure S3c for the densitometric quantification of the data shown in panel a accumulated in G1 when co-cultured with stimulated SPCs. Furthermore, stimulated PBMCs did not promote an increase of p53 in ECs, a landmark of the activation of this pathway [24] . Interestingly, it has been reported that the p21 Cip1/Waf1 -dependent cell cycle arrest by IFNc in human leukemia and melanoma cells did not correlate with p53 [55, 56] .
We identified three major pathways regulating the increase of p21 Cip1/Waf1 . STAT1, a molecule involved in the growth arrest effects of IFNs, has been reported to up-regulate p21
Cip1/Waf1 transcription through a direct binding to its promoter [36] . STAT1 phosphorylation at Y701 is mediated by Jak and is a prerequisite for STAT1 dimerization, nuclear translocation, and DNA binding [38] . In our experimental conditions, this phosphorylation was notably increased and detected in parallel with the nuclear translocation. Our data are in agreement with the observation that STAT1 depletion abrogated IFNc-induced inhibition of EC growth and in vitro morphogenesis, as well as in vivo angiogenesis promoted by vascular endothelial growth factor-A [57] . A second molecule involved is PKCd as inferred by the use of the specific inhibitor rottlein [42] and specific Figure S3d and Supplementary Table S1 for the densitometric quantification of the data shown in panel a and b, respectively siRNA oligonucleotides. In ECs co-cultured with stimulated PBMCs, PKCd silencing reduced p21 Cip1/Waf1 accumulation and rottlein inhibited the cell cycle block. This kinase generally slows proliferation and induces cell cycle arrest in different ways [58] . A first target is transcriptional and post-transcriptional regulation of cyclins D1 and E [31, 41] . A second mechanism is the elevation in p21
Cip1/Waf1 transcript and protein [31, 35, 41, 42] . To notice that in an acute promyelocytic leukemia cell line PKCd is activated in an IFNc-dependent manner and that STAT1 S727 is a substrate for its kinase activity [59] . Such serine phosphorylation does not modify the nuclear translocation of STAT1 or the DNA-binding capacity of STAT1 complexes but it is required for maximal transcriptional activation of IFNc-regulated genes [39] . In our system the maximal upregulation of p21 Cip1/Waf1 required the phosphorylation of STAT1on both Y701 and S727, suggesting the combined activity of a Jak1-and a PKCd-dependent phosphorylation of STAT1.
Although the PKCd-dependent up-regulation p21
Cip1/Waf1 is an established event in different cell systems, its precise molecular mechanism is still not fully understood. Recently, it has been reported that PKCd increases expression of Kruppel-like factor KLF4, which interacts at GC-rich DNA elements in the proximal p21 Cip1/Waf1 promoter to activate p21 Cip1/Waf1 gene transcription leading to cessation of cell proliferation [60] . Interestingly, a previous study indicated that KLF4 is a potential downstream target of IFNc that mediates its growth inhibitory property [61] .
In particular, the group of Chen and coworkers demonstrated that IFNc-induced KLF4 expression required phosphorylated STAT1 and that this effect is mediated, in part, through interaction of STAT1 with the GAS element on KLF4 promoter [62] . Therefore it is intriguing to speculate that the maximal up-regulation of p21 Cip1/Waf1 may result from the PKCd-mediated enhancement of STAT1 transcriptional activity leading to both direct and KLF4-mediated transcription of p21 Cip1/Waf1 . Lastly, we found that stimulated PBMCs utilizes the ability of p38 MAPK to stabilize p21
Cip1/Waf1 [44, 45] . Actually stimulated PBMCs activate p38 phosphorylation and p38 depletion overcomes the EC cycle arrest in G/G1 phase.
In conclusion, our findings suggest that the immune circuit activated by IL-12 arrests EC cycle in G1 phase mainly by the accumulation of CDK inhibitor p21
Cip1/Waf1 . This effect results from the cooperation between STAT1, PKCd and p38 MAPK, which act at transcriptional and post-transcriptional levels (Fig. 8) . Although the role of these pathways have not directly analyzed in vivo, our in vitro experiments suggest that they may really participate to the in vivo inhibition of EC cycle triggered by the IL-12-dependent circuit here described. Altogether, our results provide insights into the molecular mechanisms by which IL-12-activated innate immunity regulates EC proliferation in chronic degenerative diseases including tumors and atherosclerosis. Of interest, for long time IL-12 has been considered a promising therapy in the treatment of malignancies but its use has been recently discouraged for serious toxicity [8] . However recent data may allow reconsidering this cytokine as a therapeutic tool in selected tumor subsets. Actually it has been reported that the in vivo tumor response to IL-12 is influenced by the molecular features of its receptor [63] and that IL-12 could be a candidate for tumor shrinkage observed during the treatment of early-stage non-small cell lung cancer with tyrosine kinase inhibitors (vandetanib, pazopanib) targeting angiogenic receptors [64, 65] . 
